Myriad Genetics, Inc. (MYGN)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$3.19-1.24%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
QuarterlyIQ Insights · MYGN
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance dropped from the top half to the bottom half of its industry over the past month — the reason to own it has weakened.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 6.3% |
| Our one-year growth estimate | diamond | 3.7% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 2.6 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name has been missing across recent quarters and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 32 industry peers · Company calendar date is not available
MYGN — earnings miss
Dated 2026-07-30
Results of Operations and Financial Condition. On July 30, 2026, Myriad Genetics, Inc. announced its financial results for the three months ended June 30, 2026. The earnings release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements . Except for historical information contained in this Current Report on Form 8-K, including Exhibit 99.1, this Current Report on Form 8-K, including Exhib…
Why it matters: This margin range shows good cost management. It helps meet profit goals.
Supportive ifAdjusted gross margin reported between 68% and 69% in Q2.
Worry ifAdjusted gross margin is below 68%. This shows there are cost pressures.
Why it matters: Success in this project could improve efficiency and profits. It shows management's focus on costs.
Supportive ifManagement sees clear gains in efficiency or cost savings from the Ascend project.
Worry ifNo clear gains reported from the Ascend project in the next quarterly update.
Why it matters: Changes in revenue guidance show how well Myriad is handling its business.
Worry ifManagement lowers Q3 revenue guidance to less than $770 million.
Less concerning ifManagement keeps or raises Q3 revenue guidance to more than $770 million.
Why it matters: Growth in this area matters for Myriad's overall performance and future profits.
Supportive ifCancer Care Continuum revenue grows year-over-year by more than 4% in Q3.
Worry ifCancer Care Continuum revenue falls by over 4% year-over-year in Q3.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$245 on $10,000 · ±2.5% | How much price usually moves either way. |
| Bad day | $601 loss on $10,000 · 6.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $6,504 loss on $10,000 · 65.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Stable average revenue per test is key to better overall revenue.
Supportive ifAverage revenue per test increases from last quarter in Q3.
Worry ifAverage revenue per test decreases from last quarter in Q3.